secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001193125-23-160779
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia co-founder Jean-François Formela retires from board, effective June 15
-------------------------------------------------------------------------------

- Jean-François Formela, co-founder and director since 2014, resigns from board effective June 15, 2023.
- Resignation not due to any disagreement with Intellia on operations, policies, or practices.
- Formela served on Audit and Compensation and Talent Development Committees.
- No replacement was announced; board size will decrease upon his departure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523160779/0001193125-23-160779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523160779/d516011d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-160779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer